NO324378B1 - Anvendelse av en genetisk konstruert celle for fremstilling av et medikament for a indusere beskyttelse mot podingsforkastelse - Google Patents

Anvendelse av en genetisk konstruert celle for fremstilling av et medikament for a indusere beskyttelse mot podingsforkastelse Download PDF

Info

Publication number: NO324378B1
Authority: NO; Norway
Prior art keywords: cells; cell; lag; use according; gene
Prior art date: 1996-11-29

Application number

NO19992569A

Other languages

English (en)

Norwegian (no)

Other versions

NO992569D0 (no

NO992569L (no

Inventor

Mauro Biffoni

Ruben Papoian

Original Assignee

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-29

Filing date

1999-05-27

Publication date

2007-10-01

1999-05-27 Application filed by Applied Research Systems filed Critical Applied Research Systems

1999-05-27 Publication of NO992569D0 publication Critical patent/NO992569D0/no

1999-05-27 Publication of NO992569L publication Critical patent/NO992569L/no

2007-10-01 Publication of NO324378B1 publication Critical patent/NO324378B1/no

Links

230000004224 protection Effects 0.000 title claims description 18
206010052779 Transplant rejections Diseases 0.000 title claims description 16
239000003814 drug Substances 0.000 title claims description 14
238000004519 manufacturing process Methods 0.000 title claims description 10
229940079593 drug Drugs 0.000 title description 7
210000004027 cell Anatomy 0.000 claims description 146
108090000623 proteins and genes Proteins 0.000 claims description 58
102000004169 proteins and genes Human genes 0.000 claims description 25
238000001415 gene therapy Methods 0.000 claims description 24
210000000987 immune system Anatomy 0.000 claims description 24
230000014509 gene expression Effects 0.000 claims description 19
210000000056 organ Anatomy 0.000 claims description 18
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 15
108020004414 DNA Proteins 0.000 claims description 13
241001465754 Metazoa Species 0.000 claims description 9
210000002950 fibroblast Anatomy 0.000 claims description 8
210000003098 myoblast Anatomy 0.000 claims description 7
108091029865 Exogenous DNA Proteins 0.000 claims description 5
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 5
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 5
210000002889 endothelial cell Anatomy 0.000 claims description 5
210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
230000001105 regulatory effect Effects 0.000 claims description 5
102000003814 Interleukin-10 Human genes 0.000 claims description 4
108090000174 Interleukin-10 Proteins 0.000 claims description 4
239000003018 immunosuppressive agent Substances 0.000 claims description 4
229940124597 therapeutic agent Drugs 0.000 claims description 4
230000009261 transgenic effect Effects 0.000 claims description 4
230000001605 fetal effect Effects 0.000 claims description 3
229960002963 ganciclovir Drugs 0.000 claims description 3
230000006801 homologous recombination Effects 0.000 claims description 3
238000002744 homologous recombination Methods 0.000 claims description 3
210000005229 liver cell Anatomy 0.000 claims description 3
210000003606 umbilical vein Anatomy 0.000 claims description 3
108020004440 Thymidine kinase Proteins 0.000 claims description 2
230000003213 activating effect Effects 0.000 claims description 2
229940125721 immunosuppressive agent Drugs 0.000 claims description 2
238000003780 insertion Methods 0.000 claims description 2
230000037431 insertion Effects 0.000 claims description 2
230000000392 somatic effect Effects 0.000 claims description 2
102000017578 LAG3 Human genes 0.000 claims 4
101150030213 Lag3 gene Proteins 0.000 claims 4
230000001939 inductive effect Effects 0.000 claims 2
102000006601 Thymidine Kinase Human genes 0.000 claims 1
210000001519 tissue Anatomy 0.000 description 32
241000699670 Mus sp. Species 0.000 description 23
238000000034 method Methods 0.000 description 16
210000001744 T-lymphocyte Anatomy 0.000 description 15
238000002054 transplantation Methods 0.000 description 15
238000011282 treatment Methods 0.000 description 13
230000000735 allogeneic effect Effects 0.000 description 12
206010028980 Neoplasm Diseases 0.000 description 11
206010062016 Immunosuppression Diseases 0.000 description 9
230000001506 immunosuppresive effect Effects 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
150000003839 salts Chemical class 0.000 description 9
230000000694 effects Effects 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
150000001413 amino acids Chemical group 0.000 description 6
239000012634 fragment Substances 0.000 description 6
210000004988 splenocyte Anatomy 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000006870 function Effects 0.000 description 5
230000028993 immune response Effects 0.000 description 5
239000002243 precursor Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
108091005703 transmembrane proteins Proteins 0.000 description 5
102000035160 transmembrane proteins Human genes 0.000 description 5
230000001472 cytotoxic effect Effects 0.000 description 4
239000012636 effector Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
210000000822 natural killer cell Anatomy 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
239000013598 vector Substances 0.000 description 4
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
102000055025 Adenosine deaminases Human genes 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
206010011968 Decreased immune responsiveness Diseases 0.000 description 3
108010067390 Viral Proteins Proteins 0.000 description 3
230000004913 activation Effects 0.000 description 3
238000011316 allogeneic transplantation Methods 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000011260 co-administration Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
230000008021 deposition Effects 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
208000024908 graft versus host disease Diseases 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
210000004153 islets of langerhan Anatomy 0.000 description 3
230000007774 longterm Effects 0.000 description 3
210000000663 muscle cell Anatomy 0.000 description 3
210000001082 somatic cell Anatomy 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
102000053642 Catalytic RNA Human genes 0.000 description 2
108090000994 Catalytic RNA Proteins 0.000 description 2
231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 2
206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 2
206010010099 Combined immunodeficiency Diseases 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102100020880 Kit ligand Human genes 0.000 description 2
208000001388 Opportunistic Infections Diseases 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
108010039445 Stem Cell Factor Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
150000001412 amines Chemical group 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000002798 bone marrow cell Anatomy 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000005890 cell-mediated cytotoxicity Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
208000037516 chromosome inversion disease Diseases 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229940124589 immunosuppressive drug Drugs 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000007758 minimum essential medium Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
108091092562 ribozyme Proteins 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
YREOLPGEVLLKMB-UHFFFAOYSA-N 3-methylpyridin-1-ium-2-amine bromide hydrate Chemical compound O.[Br-].Cc1ccc[nH+]c1N YREOLPGEVLLKMB-UHFFFAOYSA-N 0.000 description 1
102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
206010068051 Chimerism Diseases 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
102000001039 Dystrophin Human genes 0.000 description 1
108010069091 Dystrophin Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
208000015872 Gaucher disease Diseases 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
241000696272 Gull adenovirus Species 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
102000026633 IL6 Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
102100039064 Interleukin-3 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
108700041567 MDR Genes Proteins 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282520 Papio Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
206010061334 Partial seizures Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101710114827 Protein lag-3 Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241001068295 Replication defective viruses Species 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
208000009642 Severe combined immunodeficiency due to adenosine deaminase deficiency Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
208000002903 Thalassemia Diseases 0.000 description 1
102000036693 Thrombopoietin Human genes 0.000 description 1
108010041111 Thrombopoietin Proteins 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
150000008431 aliphatic amides Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000014107 chromosome localization Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
210000001608 connective tissue cell Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000003617 erythrocyte membrane Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
201000007186 focal epilepsy Diseases 0.000 description 1
230000003325 follicular Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
230000012010 growth Effects 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000008004 immune attack Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
229940065638 intron a Drugs 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000008949 local secretion Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000005033 mesothelial cell Anatomy 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000007170 pathology Effects 0.000 description 1
108010027841 pegademase bovine Proteins 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
210000005211 primary lymphoid organ Anatomy 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000002689 xenotransplantation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Toxicology (AREA)
Transplantation (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO19992569A 1996-11-29 1999-05-27 Anvendelse av en genetisk konstruert celle for fremstilling av et medikament for a indusere beskyttelse mot podingsforkastelse NO324378B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP1996/005280 WO1998023748A1 (en)	1996-11-29	1996-11-29	Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)

Publications (3)

Publication Number	Publication Date
NO992569D0 NO992569D0 (no)	1999-05-27
NO992569L NO992569L (no)	1999-05-27
NO324378B1 true NO324378B1 (no)	2007-10-01

Family

ID=8166413

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19992569A NO324378B1 (no)	1996-11-29	1999-05-27	Anvendelse av en genetisk konstruert celle for fremstilling av et medikament for a indusere beskyttelse mot podingsforkastelse

Country Status (19)

Country	Link
US (1)	US6500422B2 (da)
EP (1)	EP0941329B1 (da)
JP (1)	JP3920928B2 (da)
KR (1)	KR100481230B1 (da)
AR (1)	AR018489A1 (da)
AT (1)	ATE271607T1 (da)
AU (1)	AU733825B2 (da)
BR (1)	BR9612821A (da)
CA (1)	CA2272130C (da)
DE (1)	DE69632967T2 (da)
DK (1)	DK0941329T3 (da)
EA (1)	EA003772B1 (da)
ES (1)	ES2225901T3 (da)
IL (1)	IL130168A (da)
NO (1)	NO324378B1 (da)
PT (1)	PT941329E (da)
UA (1)	UA73270C2 (da)
WO (1)	WO1998023748A1 (da)
ZA (1)	ZA9710737B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT941329E (pt) *	1996-11-29	2004-11-30	Applied Research Systems	Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
PL1897548T5 (pl)	2003-02-28	2025-03-17	The Johns Hopkins University	Regulacja komórek T
KR20050082389A (ko) *	2004-02-18	2005-08-23	메덱스젠 주식회사	직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
EP2044949A1 (en)	2007-10-05	2009-04-08	Immutep	Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es)	2012-07-02	2013-12-31	Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware	Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP6595458B2 (ja)	2013-09-20	2019-10-23	ブリストル−マイヤーズスクイブカンパニー	腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
GB201322626D0 (en)	2013-12-19	2014-02-05	Immutep S A	Combined preparations for the treatment of cancer
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en)	2015-01-09	2015-02-25	Immutep S A	Combined preparations for the treatment of cancer
WO2017055404A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific antibodies specific for pd1 and tim3
US11045547B2 (en)	2015-12-16	2021-06-29	Merck Sharp & Dohme Corp.	Anti-LAG3 antibodies and antigen-binding fragments
MY201482A (en)	2017-04-03	2024-02-26	Hoffmann La Roche	Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
EP4516809A3 (en)	2017-04-05	2025-09-03	F. Hoffmann-La Roche AG	Bispecific antibodies specifically binding to pd1 and lag3
CN110678200B (zh)	2017-05-30	2024-05-17	百时美施贵宝公司	包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
ES2965352T3 (es)	2017-05-30	2024-04-12	Bristol Myers Squibb Co	Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
WO2020084034A1 (en)	2018-10-26	2020-04-30	F. Hoffmann-La Roche Ag	Multispecific antibody screening method using recombinase mediated cassette exchange
KR20230093282A (ko)	2020-10-23	2023-06-27	브리스톨-마이어스 스큅 컴퍼니	폐암에 대한 lag-3 길항제 요법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2656800B1 (fr) *	1990-01-08	1992-05-15	Roussy Inst Gustave	Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5876708A (en) *	1992-02-19	1999-03-02	The General Hospital Corporation	Allogeneic and xenogeneic transplantation
CA2189657C (fr)	1994-05-06	2002-03-12	Florence Faure	Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
PT941329E (pt) *	1996-11-29	2004-11-30	Applied Research Systems	Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)

1996
- 1996-11-29 PT PT96940658T patent/PT941329E/pt unknown
- 1996-11-29 DE DE69632967T patent/DE69632967T2/de not_active Expired - Fee Related
- 1996-11-29 EA EA199900507A patent/EA003772B1/ru not_active IP Right Cessation
- 1996-11-29 EP EP96940658A patent/EP0941329B1/en not_active Expired - Lifetime
- 1996-11-29 JP JP52611398A patent/JP3920928B2/ja not_active Expired - Fee Related
- 1996-11-29 IL IL130168A patent/IL130168A/en not_active IP Right Cessation
- 1996-11-29 ES ES96940658T patent/ES2225901T3/es not_active Expired - Lifetime
- 1996-11-29 WO PCT/EP1996/005280 patent/WO1998023748A1/en not_active Ceased
- 1996-11-29 DK DK96940658T patent/DK0941329T3/da active
- 1996-11-29 KR KR10-1999-7004274A patent/KR100481230B1/ko not_active Expired - Fee Related
- 1996-11-29 UA UA99063590A patent/UA73270C2/uk unknown
- 1996-11-29 CA CA002272130A patent/CA2272130C/en not_active Expired - Fee Related
- 1996-11-29 AU AU10667/97A patent/AU733825B2/en not_active Ceased
- 1996-11-29 AT AT96940658T patent/ATE271607T1/de not_active IP Right Cessation
- 1996-11-29 US US09/319,147 patent/US6500422B2/en not_active Expired - Fee Related
- 1996-11-29 BR BR9612821-6A patent/BR9612821A/pt not_active Application Discontinuation
1997
- 1997-11-28 ZA ZA9710737A patent/ZA9710737B/xx unknown
- 1997-11-28 AR ARP970105619A patent/AR018489A1/es not_active Application Discontinuation
1999
- 1999-05-27 NO NO19992569A patent/NO324378B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2225901T3 (es)	2005-03-16
DK0941329T3 (da)	2004-11-29
NO992569D0 (no)	1999-05-27
JP3920928B2 (ja)	2007-05-30
ZA9710737B (en)	1998-07-30
JP2001505770A (ja)	2001-05-08
IL130168A0 (en)	2000-06-01
DE69632967D1 (de)	2004-08-26
UA73270C2 (en)	2005-07-15
ATE271607T1 (de)	2004-08-15
US6500422B2 (en)	2002-12-31
US20020081282A1 (en)	2002-06-27
EP0941329A1 (en)	1999-09-15
EA199900507A1 (ru)	2000-02-28
KR20000053291A (ko)	2000-08-25
NO992569L (no)	1999-05-27
PT941329E (pt)	2004-11-30
AU1066797A (en)	1998-06-22
IL130168A (en)	2006-09-05
CA2272130C (en)	2007-10-23
CA2272130A1 (en)	1998-06-04
AR018489A1 (es)	2001-11-28
EA003772B1 (ru)	2003-08-28
AU733825B2 (en)	2001-05-24
DE69632967T2 (de)	2005-08-11
BR9612821A (pt)	2000-04-11
KR100481230B1 (ko)	2005-04-07
EP0941329B1 (en)	2004-07-21
WO1998023748A1 (en)	1998-06-04
HK1023599A1 (en)	2000-09-15

Legal Events

Date	Code	Title	Description
2008-01-14	CREP	Change of representative	Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS
2008-02-04	CREP	Change of representative	Representative=s name: PROTECTOR INTELLECTUAL PROPERTY CONSULTANTS AS, PO
2010-06-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US7638498B2 (en)	2009-12-29	Substances for preventing and treating autoimmune diseases
NO324378B1 (no)	2007-10-01	Anvendelse av en genetisk konstruert celle for fremstilling av et medikament for a indusere beskyttelse mot podingsforkastelse
Follenzi et al.	2004	Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice
WO2002026827A1 (en)	2002-04-04	Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US6491925B2 (en)	2002-12-10	Compositions and methods for cancer prophylaxis and/or treatment
US8227437B2 (en)	2012-07-24	Restoration of hearing loss
Yamamoto et al.	2001	The activity of immunoregulatory T cells mediating active tolerance is potentiated in nonobese diabetic mice by an IL-4-based retroviral gene therapy
US7064111B1 (en)	2006-06-20	Use of soluble costimulatory factor for tumor immuno-gene therapy
CN1196786C (zh)	2005-04-13	抗移植排斥细胞及其用途
MXPA99004550A (en)	2000-02-02	Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
Evans et al.	1995	Section Review: Biologicals & Immunologicals: Gene therapy as a treatment for rheumatoid arthritis
HK1023599B (en)	2005-08-05	Cells for preventing graft rejection in transplantation and their uses
AU2005244520B2 (en)	2007-03-08	Substances for preventing and treating autoimmune diseases
Short	1999	Establishment of insulin synthesis and secretion by transfer of a modified human proinsulin gene into mice and cultured cells